6 results on '"Eadie, Laura N."'
Search Results
2. Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A -Rearranged Acute Lymphoblastic Leukemia.
- Author
-
Eadie, Laura N., Rehn, Jacqueline A., Breen, James, Osborn, Michael P., Jessop, Sophie, Downes, Charlotte E. J., Heatley, Susan L., McClure, Barbara J., Yeung, David T., Revesz, Tamas, Saxon, Benjamin, and White, Deborah L.
- Subjects
- *
GENE fusion , *LYMPHOBLASTIC leukemia , *ACUTE leukemia , *NEWBORN infants , *CHROMOSOMAL rearrangement , *INFANTS , *PREMATURE infants - Abstract
Chromosomal rearrangements involving the KMT2A gene occur frequently in acute lymphoblastic leukaemia (ALL). KMT2A-rearranged ALL (KMT2Ar ALL) has poor long-term survival rates and is the most common ALL subtype in infants less than 1 year of age. KMT2Ar ALL frequently occurs with additional chromosomal abnormalities including disruption of the IKZF1 gene, usually by exon deletion. Typically, KMT2Ar ALL in infants is accompanied by a limited number of cooperative le-sions. Here we report a case of aggressive infant KMT2Ar ALL harbouring additional rare IKZF1 gene fusions. Comprehensive genomic and transcriptomic analyses were performed on sequential samples. This report highlights the genomic complexity of this particular disease and describes the novel gene fusions IKZF1::TUT1 and KDM2A::IKZF1. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Rascall: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL).
- Author
-
Rehn, Jacqueline, Mayoh, Chelsea, Heatley, Susan L, McClure, Barbara J, Eadie, Laura N, Schutz, Caitlin, Yeung, David T, Cowley, Mark J, Breen, James, and White, Deborah L
- Subjects
LYMPHOBLASTIC leukemia ,ACUTE leukemia ,PHARMACOGENOMICS ,RNA sequencing ,SINGLE nucleotide polymorphisms ,MEDICAL screening - Abstract
RNA-sequencing (RNA-seq) efforts in acute lymphoblastic leukaemia (ALL) have identified numerous prognostically significant genomic alterations which can guide diagnostic risk stratification and treatment choices when detected early. However, integrating RNA-seq in a clinical setting requires rapid detection and accurate reporting of clinically relevant alterations. Here we present RaScALL, an implementation of the k-mer based variant detection tool km, capable of identifying more than 100 prognostically significant lesions observed in ALL, including gene fusions, single nucleotide variants and focal gene deletions. We compared genomic alterations detected by RaScALL and those reported by alignment-based de novo variant detection tools in a study cohort of 180 Australian patient samples. Results were validated using 100 patient samples from a published North American cohort. RaScALL demonstrated a high degree of accuracy for reporting subtype defining genomic alterations. Gene fusions, including difficult to detect fusions involving EPOR and DUX4, were accurately identified in 98% of reported cases in the study cohort (n = 164) and 95% of samples (n = 63) in the validation cohort. Pathogenic sequence variants were correctly identified in 75% of tested samples, including all cases involving subtype defining variants PAX5 p.P80R (n = 12) and IKZF1 p.N159Y (n = 4). Intragenic IKZF1 deletions resulting in aberrant transcript isoforms were also detectable with 98% accuracy. Importantly, the median analysis time for detection of all targeted alterations averaged 22 minutes per sample, significantly shorter than standard alignment-based approaches. The application of RaScALL enables rapid identification and reporting of previously identified genomic alterations of known clinical relevance. Author summary: Acute lymphoblastic leukaemia is a life-threatening malignancy characterised by various genomic alterations. RNA-sequencing (RNA-seq) is an effective method for identifying genomic lesions that drive patient disease, providing critical information about patient prognosis and treatment. However, analysis of RNA-seq data to identify clinically relevant genomic alterations is often time and resource intensive. Here, we present RaScALL, an integrated platform for rapid (Ra) screening (Sc) of RNA-seq data to identify genomic alterations of clinical significance in acute lymphoblastic leukaemia (ALL). RaScALL can detect more than 100 lesions of clinical importance from raw RNA-seq data, including gene fusions and sequence variants. A comparison of alterations detected by RaScALL and those reported by de novo variant detection tools confirmed that RaScALL is highly accurate and computationally efficient, with an average runtime of fewer than 30 minutes. Where RNA-seq data is available RaScALL provides rapid detection and reporting of prognostically significant lesions, which may ultimately assist with patient risk-stratification and therapeutic triage. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis.
- Author
-
Heatley, Susan L., Page, Elyse C., Eadie, Laura N., McClure, Barbara J., Rehn, Jacqueline, Yeung, David T., Osborn, Michael, Revesz, Tamas, Kirby, Maria, and White, Deborah L.
- Subjects
LYMPHOBLASTIC leukemia ,ACUTE leukemia ,INDIVIDUALIZED medicine ,NEUROFIBROMATOSIS ,ACUTE myeloid leukemia - Abstract
Children with neurofibromatosis have a higher risk of developing juvenile myelomonocytic leukemia and acute myeloid leukemia, but rarely develop B-cell acute lymphoblastic leukemia (B-ALL). Through in-vitro modeling, a novel NF1 p.L2467 frameshift (fs) mutation identified in a relapsed/refractory Ph-like B-ALL patient with neurofibromatosis demonstrated cytokine independence and increased RAS signaling, indicative of leukemic transformation. Furthermore, these cells were sensitive to the MEK inhibitors trametinib and mirdametinib. Bi-allelic NF1 loss of function may be a contributing factor to relapse and with sensitivity to MEK inhibitors, suggests a novel precision medicine target in the setting of neurofibromatosis patients with B-ALL. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
- Author
-
Tavakoli Shirazi, Paniz, Eadie, Laura N., Page, Elyse C., Heatley, Susan L., Bruning, John B., and White, Deborah L.
- Subjects
- *
LYMPHOBLASTIC leukemia , *ACUTE leukemia , *HISTONE deacetylase inhibitors , *CHIMERIC proteins , *HISTONE deacetylase , *B cells , *PROTEIN metabolism , *PROTEINS , *RESEARCH , *HETEROCYCLIC compounds , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *CELLULAR signal transduction , *COMPARATIVE studies , *TRANSFERASES , *GENES , *SULFONES , *CARRIER proteins , *DRUG resistance in cancer cells - Abstract
Activating TYK2-rearrangements have recently been identified and implicated in the leukemogenesis of high-risk acute lymphoblastic leukemia (HR-ALL) cases. Pre-clinical studies indicated the JAK/TYK2 inhibitor (JAKi), cerdulatinib, as a promising therapeutic against TYK2-rearranged ALL, attenuating the constitutive JAK/STAT signaling resulting from the TYK2 fusion protein. However, following a period of clinical efficacy, JAKi resistance often occurs resulting in relapse. In this study, we modeled potential mechanisms of JAKi resistance in TYK2-rearranged ALL cells in vitro in order to recapitulate possible clinical scenarios and provide a rationale for alternative therapies. Cerdulatinib resistant B-cells, driven by the MYB-TYK2 fusion oncogene, were generated by long-term exposure to the drug. Sustained treatment of MYB-TYK2-rearranged ALL cells with cerdulatinib led to enhanced and persistent JAK/STAT signaling, co-occurring with JAK1 overexpression. Hyperactivation of JAK/STAT signaling and JAK1 overexpression was reversible as cerdulatinib withdrawal resulted in re-sensitization to the drug. Importantly, histone deacetylase inhibitor (HDACi) therapies were efficacious against cerdulatinib-resistant cells demonstrating a potential alternative therapy for use in TYK2-rearranged B-ALL patients who have lost response to JAKi treatment regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy.
- Author
-
Heatley, Susan L., Asari, Kartini, Schutz, Caitlin E., Leclercq, Tamara M., McClure, Barbara J., Eadie, Laura N., Hughes, Timothy P., Yeung, David T., and White, Deborah L.
- Subjects
LYMPHOBLASTIC leukemia ,GENE fusion ,ACUTE leukemia ,CHILD mortality ,PROTEIN-tyrosine kinases ,CD19 antigen ,GASTROINTESTINAL stromal tumors - Abstract
Acute lymphoblastic leukemia remains a leading cause of cancer-related death in children. Furthermore, subtypes such as Ph-like ALL remain at high-risk of relapse, and treatment resistance remains a significant clinical issue. The patient-derived Ph-like ALL RANBP2-ABL1 fusion gene was transduced into Ba/F3 cells and allowed to become resistant to the tyrosine kinase inhibitors (TKIs) imatinib or dasatinib, followed by secondary resistance to ponatinib. RANBP2-ABL1 Ba/F3 cells developed the clinically relevant ABL1 p.T315I mutation and upon secondary resistance to ponatinib, developed compound mutations, including a novel ABL1 p.L302H mutation. Significantly, compound mutations were targetable with a combination of asciminib and ponatinib. In-vitro modeling of Ph-like ALL RANBP2-ABL1 has identified kinase domain mutations in response to TKI treatment, that may have important clinical ramifications. Early detection of mutations is paramount to guide treatment strategies and improve survival in this high-risk group of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.